Research programme: small molecules - BioAge Labs
Latest Information Update: 29 Apr 2021
At a glance
- Originator BioAge Labs; HitGen
- Developer BioAge Labs
- Class Antidementias; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Cardiovascular disorders